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INTRODUCTION
 Congenital hypothyroidism (CH), with a 
prevalence of 1/3000-4000 live births, is the most 
common endocrine disorder and preventable cause 
of childhood mental retardation.1,2 CH is considered 
as a multifactorial disease and many genetical, 
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ABSTRACT
Objective: The prevalence of congenital hypothyroidism (CH) is high in Isfahan, Iran. In addition, 
it has different etiologies compared with other countries. The rate of parental consanguinity is 
also high in the city. Moreover, DUOX2 gene is effective in transient CH and permanent CH due 
to dyshormonogenesis. Therefore, the aim of this research was to investigate the mutations of 
DUOX2 gene in patients with transient CH and permanent CH due to dyshormonogenesis.
Methodology: In this descriptive, prospective study, patients diagnosed with transient 
and permanent CH due to dyshormonogenesis during CH screening program were selected. 
Venous blood samples were obtained to determine the 3 mutations (Q36H, R376W, and 
D506N) of DUOX2 gene using polymerase chain reaction (PCR) method by specific primers and 
complementary methods such as restriction fragment length polymorphism (RFLP) and single-
strand conformation polymorphism (SSCP).
Results: In this study, 25 patients with transient CH and 33 subjects with permanent CH due to 
dyshormonogenesis were studied. In addition, 30 children were studied as the control group. 
We did not find any mutations of the 3 mentioned mutations of DUOX2 gene.
Conclusion: Considering the findings of the current study, further studies with other methods 
are required to evaluate other gene mutations such as pendrin, sodium-iodide symporter (NIS) 
and thyroglobulin.
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environmental and autoimmune factors contribute 
in its pathogenesis.3-5 It could be presented in 
transient or permanent forms. In the transient form, 
the need for thyroid replacement therapy would be 
temporary, i.e. for the first 1-3 years, while in the 
permanent form, treatment would be continued 
lifelong.6 The causes of transient CH are excessive or 
lack of iodine intake and transplacental migration 
of antibodies and antithyroid drugs.6 Permanent 
CH in 85% of cases is associated with a spectrum of 
thyroid gland developmental defects (dysgenesis) 
due to abnormal differentiation, migration, or 
growth of the gland. In 10-20% of cases, it results 
from defects in one of the multiple steps of thyroid 
hormone synthesis or defects in the receptor of 
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thyroid hormone (dyshormonogenesis) which is 
a heritable disorder represented by goiter in some 
cases.6
 Thyroid dysgenesis is a sporadic disorder whose 
pathogenesis is still unknown. On the contrary, 
several molecular studies have found different 
genes, including thyroid stimulating hormone re-
ceptor (TSHR), sodium-iodide symporter (NIS), 
thyroglobulin (TG), thyroid peroxidase (TPO) and 
pendrin, to be involved in thyroid dyshormono-
genesis. Recently, dual oxidase 2 (DUOX2) has been 
identified as a new gene involved in the etiology of 
dyshormonogenesis.7-11
 Hydrogen peroxide (H2O2) is considered as an 
essential compound for thyroid hormone formation 
and has an important role in the initial step of trii-
odothyronine (T3) and thyroxine (T4) synthesis in 
the follicular lumen of thyrocytes. This biochemical 
requirement of H2O2 for thyroid hormone produc-
tion has been known as H2O2-generating system. 
DUOX2, a reduced nicotinamide adenine dinu-
cleotide (NAD) phosphate: O2 oxidoreductase fla-
voprotein located at the apical plasma membrane 
of thyrocytes, is a component of the thyroid H2O2-
generating system. It is a 1548-aminoacid polypep-
tide, including a 26-amino-acid signal peptide. Its 
gene is located on chromosome 15 and consists of 
33 exons encoding an mRNA with 6376 nucleotides. 
This polypeptide is involved in the Ca2+/reduced 
nicotinamide adenine dinucleotide phosphate-de-
pendent H2O2 generation. H2O2 is used by TPO 
to catalyze both the iodination of tyrosine residues 
and the coupling of iodotyrosine residues of TG. 
DUOX2 is considered as the principal element in 
generating the H2O2 needed for TPO function.12-17
 Previous studies have indicated that a defect in 
the H2O2-generating system causes congenital hy-
pothyroidism. They have suggested that biallelic 
mutations of DUOX2 cause permanent congenital 
hypothyroidism and that monoallelic mutations 
cause transient congenital hypothyroidism.18,19 
However, some studies have reported transient CH 
cases, despite biallelic mutations. In addition, famil-
ial cases of DUOX2 have also been reported.18
 The prevalence of CH is high in Isfahan. Moreo-
ver, it has different etiologies compared to other 
countries. The prevalence of transient CH and also 
the rate of permanent CH due to dyshormonogene-
sis are high according to CH screening results.20 On 
the other hand, high rate of parental consanguin-
ity can be effective on CH incidence.21 Moreover, 
DUOX2 gene is involved in transient CH and per-
manent CH due to dyshormonogenesis.
Therefore, the aim of this research was to 
investigate the mutations of DUOX2 gene in 
patients with transient CH and permanent CH due 
to dyshormonogenesis in Isfahan, Iran.
METHODOLOGY
 In this descriptive, prospective study, patients 
diagnosed with transient CH or permanent CH due 
to dyshormonogenesis in Isfahan Endocrine and 
Metabolism Research Center, during CH screening 
program (2002-2009) in Isfahan were selected. 
CH screening program was initiated in 2002 and 
continued until 2005 when the nationwide CH 
screening program was implemented.
 Newborns with abnormal screening results were 
re-examined and those with abnormal T4 and TSH 
levels on their second measurement (TSH > 10 
mIU/l and T4 < 6.5 µg/dl) were diagnosed as CH 
patients and received treatment and regular follow-
up. Hypothyroid neonates underwent treatment at 
a dose of 10-15 µg/kg/day as soon as the diagnosis 
was confirmed. The TSH and T4 levels were moni-
tored during the follow-up.
 Permanent and transient cases of CH were deter-
mined at the age of three years old by measuring 
TSH and T4 concentrations four weeks after with-
drawal of L-T4 therapy. Patients with elevated TSH 
levels (TSH > 10 mIU/l) and decreased T4 levels 
(T4 < 6.5 µg/dl) were considered as permanent CH 
sufferers. The etiology of CH was determined by 
thyroid scan and/or ultrasound before treatment 
in neonatal period or at the age of 3 years old after 
confirming the permanency of CH. Patients with 
thyroid gland of normal size were considered to 
have dyshormonogenesis.20
 The protocol was approved by the Institutional 
Review Board and Medical Ethics Committee of 
Isfahan University of Medical Sciences. Written 
consents were obtained from the parents of CH 
patients.
 The selected CH patients were examined by a 
pediatrician and the demographic characteristics 
and screening findings regarding the level of TSH 
and T4, parental consanguinity and the etiology of 
CH were recorded using a questionnaire.
 Venous blood samples were obtained from the se-
lected patients. The samples were transferred to the 
Department of Genetics, Isfahan University of Med-
ical Sciences for molecular analysis and determin-
ing the 3 mutations (Q36H, R376W, and D506N) of 
DUOX2 gene using the polymerase chain reaction 
(PCR) method by specific primers and complemen-
tary methods such as restriction fragment length 
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polymorphism (RFLP) and single-strand conforma-
tion polymorphism (SSCP).
Genetic study: DNA was extracted from peripheral 
blood by the QIAamp DNA Blood Mini Kit (Qiagen, 
Germany). Real-time PCR and melting curve 
analysis were performed in the Corbett Rotor-
Gene 6000 instrument (Corbett Research, Sydney, 
Australia).
 Primers were designed by Beacon Designer 7.91 
to flank the coding regions (Premier Biosoft Inter-
national, USA) and synthesized by TIB MolBiol 
(Germany). The primers included Q36H forward 
primer (5’-GGGAGGGGTAGCTGGGAGC-3’) 
and reverse primer (5’- CCGCTCAGGGC-
CTTTCGC-3’), R376W forward primer (5’-TCC-
CTCACCACATCCTTTGTTCTCA-3’) and reverse 
primer (5’- TGTTGCTTTTCCCAGCCTGTGTG-3’), 
and D506N forward primer (5’-CATGGGGAC-
CCTGGACCC) and reverse primer (5’- GTGTG-
GTGGGCTGACTGGG-3’). The final optimal re-
action conditions were empirically determined. 
The reaction mixture used was Type-it HRM 
Kit (Qiagen, Germany).
 The amplification mixture of a total volume of 25 
μL included 12.5 μL of high resolution melt (HRM) 
PCR master mix, 1.75 μL of 10 μM primer mix, 2 μL 
of genomic DNA as template and 8.25 μL of RNase-
free water. The PCR cycling conditions are reported 
in Tables II-IV. The HRM analysis was performed 
by instrument software, which allows clustering 
the samples into groups on the basis of difference 
plots obtained by analyzing the differences in melt-
ing curve shapes.
 One sample from each group with less than 90% 
confidence was confirmed by sequencing PCR 
products in the 3730xl Genetic Analyzer (Bioneer, 
South Korea).
Statistical Analysis: The obtained data was 
analyzed using the SPSS13 (SPSS Inc., Chicago, IL, 
U.S.A.).
RESULTS
 In this study, 25 patients with transient CH and 33 
cases of permanent CH due to dyshormonogenesis 
were studied. Thirty children were studied as the 
control group. Demographic characteristics of the 
studied population are presented in Table-I. The 
difference plot showed the approximately same 
shapes detected in the same amplicons (Fig. 1-3). 
Sequencing analysis did not show different results. 
We did not find any of the three mentioned DUOX2 
gene mutations (Q36H, R376W, and D506N).
DISCUSSION
 Similar to other etiological investigations during 
the CH screening in Isfahan, this study evaluated the 
role of three mutations of DUOX2 (Q36H, R376W, 
and D506N) in transient CH patients and permanent 
Mutations of Dual Oxidase 2 (DUOX2) Gene in Permanent & Transient Congenital Hypothyroidism
Table-I: Demographic characteristics of patients with transient and permanent 
CH due to dyshormonogenesis and the control group.
 Patients with transient CH Patient with permanent CH Control group
  due to dyshormonogenesis
Age (months) 68.2 ± 25.5 64.6 ± 23.7 69.3 ± 27.2
Sex (male/female) 18/7 15/18 19/11
Parental consanguinity (%) 69% 62% 39%
TSH (mIU/l)   
-primary 25.5 ± 19.7 47.3 ±46.1 4.5 ± 2.7
-after treatment interruption 3.9 ± 2.0 36.5 ± 30.7 -
T4 (µg/dl)   
-primary 5.7 ± 3.5 6.2 ± 3.5 11.6 ± 3.9
-after treatment interruption 8.1 ± 1.9 7.1 ± 2.9 -
Fig.1:  Sequencing analysis of the Q36h mutation. Fig.2: Sequencing analysis of R376W mutation.
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CH patients due to dyshormonogenesis. According 
to our results, the studied population, including 
both transient and permanent CH patients, did not 
have any of the mentioned mutations.
 Many human and animal studies have suggested 
the important role of DUOX2 gene in the synthesis 
of thyroid hormone and the etiology of CH.22 
The mentioned association have mostly been 
recognized by the neonatal screening test for CH 
since it is difficult to diagnose adult cases of DUOX2 
mutation. The role of DUOX2 gene mutation in CH 
was reported by Moreno et al. in 2002 for the first 
time.18 Since then, several studies indicated different 
mutations of DUOX2 gene to be responsible for 
transient and permanent CH. Overall, 20 mutations 
have been reported from which 11 are located in the 
first long intracellular loop, 8 in the extracellular 
peroxidase-like domain and one in the second 
intracellular loop. The types of identified mutations 
include missense, nonsense, frame shift and splice-
site mutations.23
 It has been proposed that biallelic and monoal-
lelic mutations of the gene cause permanent and 
transient CH, respectively. However, some studies 
have also reported biallelic mutations of DUOX2 
gene among transient CH cases, which suggests the 
presence of an alternative mechanism for produc-
ing H2O2 in complete defect of DUOX2 gene. Fa-
milial cases of CH with heterozygous mutations of 
DUOX2 have also been reported.18,19
 In addition, an identical DUOX2 mutation could 
be present with a high intra- and inter-familial phe-
notypic variability. Vigone et al have reported that 
two siblings with the same identical DUOX2 muta-
tion had different clinical phenotypes.24 This vari-
ability of the DUOX2 phenotype could be explained 
by some hypotheses such as the existence of other 
H202 generating systems, the different require-
ments for thyroid hormones synthesis according to 
age, the ethnicity and the intake of iodine.24,25 Ge-
netic studies have showed some factors as DUOX2 
maturation factors which enhance the endoplasmic 
reticulum (ER)-to-Golgi transition, maturation and 
surface expression of functional DUOX2 in a het-
erologous cell system. In this regard, three natural 
missense mutations including Q36H, R376W, and 
D506N have been reported. They were also evalu-
ated in the current study. These mutations cause 
partial (D506N) or complete (Q36H and R376W) 
loss of H2O2 generating system activity which con-
sequently results in iodine organification defect. 
The defects caused by these mutations are made by 
trafficking defects of the mutant proteins resulting 
in complete retention in the ER due to Q36H and 
R376W mutations or reduced plasma membrane 
translocation due to D506N mutation.26
 Considering the key role of the mentioned 
mutations in the synthesis of thyroid hormone and 
iodine organification process, we investigated the 
role of these three mutations of the peroxidase-like 
domain. The mentioned three mutations have been 
identified during the CH screening programs. For 
the first time, the mutation of R376W, Q36H and 
D506N were reported by Vigone et al in 2005,24 Varela 
et al in 2006,27 and Pfarr et al in 2006,28 respectively. 
Afterwards, Grasberger et al performed a functional 
study and analyzed the three mutations in Cos-7 
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Table-II: The PCR cycling conditions
for determining the Q36H mutation.
Cycle Cycle Point
Hold @ 95°c, 6 min 0 secs   
Cycling (45 repeats)  Step 1 @ 95°c, hold 12 secs
  Step 2 @ 55°c, hold 31 secs
  Step 3 @ 72°c, hold 16 secs,
Melt (60-90°c), hold secs on 
the 1st step, hold 2 secs on next steps, Melt A([HRM]
Fig.3: Sequencing analysis of the D506N mutation.
Table-III: The PCR cycling conditions 
for determining the R376W mutation.
Cycle Cycle Point
Hold @ 95°c, 5 min 0 secs   
Cycling (45 repeats)  Step 1 @ 95°c, hold 11 secs
  Step 2 @ 59°c, hold 24 secs
  Step 3 @ 72°c, hold 15 secs, 
Melt (70-95°c), hold secs on 
the 1st step, hold 2 secs on next steps, Melt A([HRM]
Table-IV: The PCR cycling conditions for 
determining the D506N mutation.
Cycle Cycle Point
Hold @ 95°c, 5 min 0 secs   
Cycling (45 repeats)  Step 1 @ 95°c, hold 11 secs
  Step 2 @ 59°c, hold 24 secs
  Step 3 @ 72°c, hold 15 secs,
Melt (70-95°c), hold secs on
the 1st step, hold 2 secs on next steps, Melt A([HRM]
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cells. According to their findings, due to complete 
inhibition of the transition of DUOX from the ER 
to the plasma membrane by Q36H and R376W 
mutations or partial (D506N) inhibition of H2O2-
generating system activity by these mutations, 
these DUOX2 mutants were retained within the ER. 
They suggested that post-transitional processing of 
the peroxidase-like domain had an important role 
in the exit of DUOX2 from ER.26
 We did not find any mutation of the mentioned 
three mutations (Q36H, R376W, and D506N) of 
DUOX2 gene among either group of transient or 
permanent CH patients in the current study. The 
most important explanation for this finding could 
be the ethnical variation in the genes involved in 
thyroid hormonogenesis as reported by other 
studies.29 Mutations in other genes involved in the 
pathogenesis of transient and permanent CH due 
to dyshormonogenesis, such as NIS gene, pendrin 
gene (PDS) and thyroglobulin gene, may have had 
a role in our studied population. However, such 
hypothesis needs further investigations.
 On the other hand, previous studies have indi-
cated that some factors such as age, ethnicity, and 
iodine intake could explain the different phenotype 
variations of an identical DUOX2 gene mutation. 
The mentioned factors could also have a role in 
different mutations of thyroid hormone synthesis. 
The sample size was enough for the purpose of the 
study and so it could not be considered as a limiting 
factor in this field.
 Our finding could also be explained by different 
factors related to the method of the genetic study. In 
the current study, only the exonic parts of the genes 
were analyzed. However, mutations in intronic se-
quences or in the promoter region and unexamined 
regulatory regions of the three studied genes could 
have been the causes of thyroid dyshormonogen-
esis or transient CH in these patients.30
 Another explanation is that although the method 
used in this study has a high sensitivity, it is high-
ly dependent on laboratory conditions. Therefore, 
some mutations with slight impacts on changes in 
single-strand confirmation could not be detected by 
this method. Thus, some existing mutations might 
have remained unidentified with SSCP.31
 The limitation of this research was that we did 
not determine iodine organification defects in the 
studied patients due to insufficient facilities to per-
form perchlorate discharge test. In addition, it is 
necessary to examine other identified mutations of 
DUOX2 gene in the studied population.
 In conclusion, the results of this study 
indicated that the mutations of the peroxidase-
like domain of DUOX2 did not have a role in the 
pathogenesis of transient and permanent CH due to 
dyshormonogenesis in this population. However, 
for more conclusive results, further studies 
using another screening method besides SSCP, 
and screening of intronic mutations and other 
identified DUOX2 gene mutations on the other 
sites of the gene are recommended. Investigation 
of other gene mutations responsible for thyroid 
dyshormonogenesis and transient CH such as 
pendrin, NIS and thyroglobulin is recommended, 
too.
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